β-arrestin 2 as an activator of cGAS-STING signaling and target of viral immune evasion

Yihua Zhang1,5, Manman Li1,5, Liuyan Li1, Gui Qian1, Yu Wang2, Zijuan Chen1, Jing Liu1, Chao Fang3, Feng Huang4, Daqiao Guo3, Quanming Zou2, Yiwei Chu1 & Dapeng Yan1

Virus infection may induce excessive interferon (IFN) responses that can lead to host tissue injury or even death. β-arrestin 2 regulates multiple cellular events through the G protein-coupled receptor (GPCR) signaling pathways. Here we demonstrate that β-arrestin 2 also promotes virus-induced production of IFN-β and clearance of viruses in macrophages. β-arrestin 2 interacts with cyclic GMP-AMP synthase (cGAS) and increases the binding of dsDNA to cGAS to enhance cyclic GMP-AMP (cGAMP) production and the downstream stimulator of interferon genes (STING) and innate immune responses. Mechanistically, deacetylation of β-arrestin 2 at Lys171 facilitates the activation of the cGAS–STING signaling and the production of IFN-β. In vitro, viral infection induces the degradation of β-arrestin 2 to facilitate immune evasion, while a β-blocker, carvedilol, rescues β-arrestin 2 expression to maintain the antiviral immune response. Our results thus identify a viral immune-evasion pathway via the degradation of β-arrestin 2, and also hint that carvedilol, approved for treating heart failure, can potentially be repurposed as an antiviral drug candidate.
Viruses are worldwide issues that threaten human health and lead to huge economic losses and social problems. The emergence of the novel coronavirus, SARS-CoV-2, has resulted in a tremendous public health crisis in China that is also having an impact at a global level. As the first line of immune response, the innate immunity is activated by recognizing pathogen-associated molecular patterns (PAMPs) through a set of pattern recognition receptors (PRRs), which can subsequently regulate the adaptive immunity and together eliminate the viruses. Despite the diversity of viruses, host immune cells are able to evolve various PRRs and innate immune signaling pathways to detect the PAMPs. Toll-like receptors (TLRs), retinoic acid-inducible gene 1 (RIG-I)-like receptors (RLRs), and DNA sensors recognize viral nucleic acids and initiate downstream signal transduction, resulting in the induction of type I interferons (IFNs) and other proinflammatory cytokines to protect the host against virus infection. The endosomal TLRs recognize viral double-stranded RNA (dsRNA; TLR3, single-stranded RNA (ssRNA; TLR7/8), or unmethylated CpG sequences in the DNA (TLR9), and RIG-I and melanoma differentiation-associated gene 5 (MDA5) are known to recognize viral dsRNA. In addition, DNA sensors, such as cyclic GMP-AMP synthase (cGAS), recognize dsDNA and cDNA that are reverse-transcribed from RNA in RNA viruses, such as HIV-1, to produce cGAMP and subsequently activates STING. STING recruits and activates TBK1 and IRF3, and induces the production of type I IFNs and proinflammatory cytokines. The enzymatic function of cGAS is achieved by the C-terminal part, which possesses nucleotidylytransferase activity and MB21 domains along with DNA-binding sites. The interaction between cGAS and viral DNA in the cytosol induces the formation of liquid-like droplets, resulting in the conformational change and oligomerization of cGAS, which promotes the activation of the enzyme activity of cGAS. Except for the pivotal role of cGAS in virus infection, cGAS is important for maintaining homeostasis in several cells. Numerous studies have reported that cGAS could be regulated by several posttranslational modifications, including sumoylation, acetylation, and ubiquitination. On the other hand, although cGAS acts as a cytosolic DNA sensor that initiates the STING–TBK1–IRF3-type I IFN signaling cascade, the location of cGAS largely influences its functions. cGAS not only activates downstream ERK activation in a dimerization-dependent manner but also demonstrate that carve-dilol can be a potential antiviral drug candidate by promoting β-arrestin 2 expression.

**Results**

**Deficiency of β-arrestin 2 decreases cellular antiviral responses.** To investigate the function of β-arrestin 2 in the antiviral innate immune response, we analyzed β-arrestin 2 expression in peritoneal macrophages after infection with herpes simplex virus 1 (HSV-1) or vesicular stomatitis virus (VSV). We observed that β-arrestin 2 protein level was decreased (Fig. 1a and Supplementary Fig. 1a), whereas the abundance of mRNA expression of β-arrestin 2 was not affected by the virus infection (Fig. 1b), indicating that β-arrestin 2 is probably degraded by viruses in a posttranslational manner.

We then prepared peritoneal macrophages from wild-type (WT) and Arrb2−/− mice and stimulated them with HSV-1, VSV, Sendai virus (SeV), or DNA mimics. The expression of Ifnb, Isg15, and Ccl5 was significantly downregulated in Arrb2−/− macrophages compared with all types of stimulations compared with the expression of these genes in their WT counterparts (Fig. 1c, d and Supplementary Fig. 1b–e). Consistent with this finding, the virus titers were much higher in Arrb2−/− macrophages than in WT macrophages (Fig. 1e, f). We next analyzed the activation of the major pathways that are involved in virus infection, including type I IFN, NF-κB, and MAPK pathways. We observed that HSV-1 and VSV infection induced reduced phosphorylation of TBK1, IRF3, IRF7, and STING in Arrb2−/− macrophages than in WT macrophages (Fig. 1g, h). However, the phosphorylation of p65, p38, ERK, and Jnk remained unaffected, indicating that β-arrestin 2 primarily promotes the IFN-β signaling pathway to regulate the antiviral innate immune response. The dimerization and the translocation of IRF3 are essential for the production of IFN-β during virus infection. As expected, the dimerization (Fig. 1i, j) and translocation (Fig. 1k, l and Supplementary Fig. 1f) of IRF3 in β-arrestin 2−/− macrophages were significantly reduced compared with those in WT macrophages.

To further confirm the function of β-arrestin 2, we transfected RAW264.7 cells with the negative control small interfering RNA (siRNA) or β-arrestin 2-specific siRNA and confirmed that only β-arrestin 2-specific siRNA decreased β-arrestin 2 expression (Supplementary Fig. 1g, h). As anticipated, HSV-1, VSV, ISD, and RNA mimics poly(I:C) stimulated much lower expression of Ifnb, Isg15, and Ccl5 in β-arrestin 2 knockdown cells (Fig. 1m and Supplementary Fig. 1i–l). Meanwhile, the titers of HSV-1 and...
VSV were increased in β-arrestin 2 knockdown cells (Fig. 1n). Consistent with the cytokine levels, the knockdown of β-arrestin 2 significantly reduced the phosphorylation of TBK1, IRF3, IRF7, and STING (Fig. 1o, p) and also the dimerization of IRF3 (Fig. 1q) during virus infection. Altogether, these results suggested that β-arrestin 2 promoted the IFN-β signaling and the antiviral immune response induced by RNA or DNA virus.

β-arrestin 2 positively regulates IFN-β signaling. Next, we investigated whether β-arrestin 2 overexpression had a substantial effect on IFN-β signaling. We observed that in L929 mouse fibroblast cells, β-arrestin 2 overexpression significantly increased the HSV-1- or VSV-induced expression of Ifnb, Isg15, and Ccl5 (Fig. 2a, b). Similar results were obtained when poly(I:C) or ISD was used as a stimulus (Fig. 2c, d). Consistent with this finding,
Deficiency of β-arrestin 2 diminished the antiviral immune response in vivo. To investigate the function of β-arrestin 2 in the antiviral innate immune response in vivo, we infected 6-week-old homozygous Arrb2+/− mice and their WT counterparts with HSV-1 (2 × 10^5 PFU/mouse) or VSV (5 × 10^5 PFU/mouse) and evaluated the expression levels of Ifnb, Isg15, and Ccl5 in different tissues. After the infection of mice with HSV-1, the expression levels of Ifnb, Ccl5, and Isg15 were significantly lower in the spleens, livers, and lungs of Arrb2+/− mice than in those of WT mice (Fig. 3a). Consistent with this result, we observed significantly higher HSV-1 titers in the spleens, livers, and lungs of Arrb2+/− mice than in those of WT mice (Fig. 3a). Consistent with this result, we observed significantly higher HSV-1 titers in the spleens, livers, and lungs of Arrb2+/− mice than in those of WT mice (Fig. 3b). Similar results were obtained when VSV was used as a stimulus (Fig. 3c, d). In agreement with these results, we observed more injury in the lungs and spleens of Arrb2+/− mice than in those of WT mice (Fig. 3c, f). We further compared the survival rates between WT and Arrb2+/− mice after infection with HSV-1 or VSV and observed that Arrb2+/− mice were more susceptible to HSV-1 or VSV and suffered higher mortality than their WT counterparts (Fig. 3g, h). All these in vivo results indicated that β-arrestin 2 was a critical positive regulator of the antiviral immune response to both RNA and DNA viruses.

β-arrestin 2 interacts with cGAS and promotes the activation of cGAS. To further investigate the function of β-arrestin 2 in host antiviral immunity against virus infection, we performed RNA-seq analyses of WT and Arrb2+/− PMs infected with HSV-1. Compared to WT group, Arrb2+/− group significantly altered the expression of 859 genes (251 upregulated and 608 downregulated) (Fig. 4a and Supplementary Fig. 2a). The PPI analyses based on differential genes showed a close interaction network among host antiviral genes, such as Isg15, Cxcl10, Isg20, IFTT family genes, and so on (Supplementary Fig. 2b). Consistently, functional classification analysis of the downregulated genes revealed an enrichment in positive regulation genes of host defense response to virus (Supplementary Fig. 2c). Gene ontology analyses showed that Arrb2+/− group downregulated the expression of multiple genes related to response to external stimulus, immune response, inflammatory response, innate immune response, response to virus, etc (Fig. 4b and Supplementary Fig. 2d). Similarly, KEGG analyses revealed an enrichment of the differential genes in cytokine–cytokine receptor interaction, chemokine signaling pathway, primary immunodeficiency, Jak–STAT signaling pathway, cytosolic DNA-sensing pathway, and so on (Fig. 4c and Supplementary Fig. 2e). We next aimed to determine the mechanism through which β-arrestin 2 promotes IFN-β signaling. To identify the component in IFN-β signaling that was affected by β-arrestin 2, we performed a dual-luciferase assay through overexpressing β-arrestin 2 in HEK293T cells in the presence or absence of expression vectors for RIG-I-N, MAVS, cGAS plus STING, TBK1, or constitutively active IRF3 (termed as "IRF3-5D") here. Our results revealed that β-arrestin 2 overexpression promoted the activity of luciferase reporters for above signaling proteins-induced IFN-β and ISRE activation except for IRF3-5D (Fig. 4d, e), suggesting that β-arrestin 2 promoted the activation of signaling proteins upstream of IRF3. A co-immunoprecipitation-based screening experiment demonstrated that β-arrestin 2 interacted with only cGAS (Fig. 4f, g), but not with other proteins in the IFN-β signaling pathway. We next used E. coli to express and purify GST-cGAS and His-β-arrestin 2. Using these purified proteins in an in vitro GST precipitation assay, we found that cGAS directly bound with β-arrestin 2 (Fig. 4h). The luciferase assay demonstrated that β-arrestin 2 promoted cGAS plus STING-triggered activation of the IFNB and ISRE promoters in a dose-dependent manner (Fig. 4i, j). To further study which domains of cGAS and β-arrestin 2 are involved in their interaction, we constructed a series of truncation mutants of cGAS and β-arrestin 2, respectively. We found, using truncated proteins, that sequence regions 1–185 of β-arrestin 2 and 213–522 of cGAS were important for their interactions (Supplementary Fig. 2f, g).

Recognition of dsDNA by cGAS produces cGAMP and subsequently activates STING, which activates IFN-β signaling transduction. As β-arrestin 2 was found to interact with cGAS, we assessed the effect of β-arrestin 2 on the binding of dsDNA and cGAS. We used a pull-down assay to immunoprecipitate biotin-labeled dsDNA with streptavidin and found that β-arrestin 2 significantly increased the amount of cGAS pulled down by dsDNA (Fig. 4k), indicating that β-arrestin 2 improved the DNA-binding ability of cGAS. We also found that β-arrestin 2 could promote cGAS and DNA-binding activity in vitro using purified proteins by EMSA (Fig. 4l). As cGAS forms dimers after dsDNA binding, we next aimed at investigating whether β-arrestin 2 influenced the formation of cGAS dimers. Our results revealed that β-arrestin 2 overexpression significantly increased the amount of cGAS pulled down by dsDNA.
Fig. 2 β-arrestin 2 positively regulates IFN-β signaling. a–d Ifnb, lsg15, and Ccl5 mRNA levels in L929 cells transfected with control or β-arrestin 2 vectors and stimulated with HSV-1 a (**P = 0.0018, ***P < 0.0001, < 0.0001 in sequence, left panel; **P = 0.0040, 0.0028, 0.0050 in sequence, middle panel; ***P = 0.0006, **P = 0.0044, 0.0010 in sequence, right panel), VSV b (**P < 0.0001, **P = 0.0015, 0.0071 in sequence, left panel; ***P < 0.0001, < 0.0001 in sequence, middle panel; ***P < 0.0001, < 0.0001, = 0.0009 in sequence, right panel), ISD c (**P < 0.0001, left panel; ***P = 0.0004, middle panel; **P = 0.0025, right panel), or poly(I:C) d (**P < 0.0001, left panel; ***P < 0.0001, middle panel; **P = 0.0067, right panel) for indicated times. e, f The virus titers as in a or b for 72 h (**P = 0.0013 in e, **P = 0.0062 in f). g–h Immunoblot of lysates of L929 cells transfected with control or β-arrestin 2 vectors and infected with HSV-1 g or VSV h for indicated times. i, j Immunoblot analysis of monomeric and dimeric STING i and IRF3 j as in g or h. k, l Immunoblot analysis of nuclear and cytoplasmic fractions as in i or j. Data are representative of at least three independent experiments (mean ± SEM in a–f, n = 3). Two-tailed unpaired Student’s t-test.
Fig. 3 Deficiency of β-arrestin 2 diminished the antiviral immune response in vivo. a I fb, lsg15, and Ccl5 mRNA levels in the spleens, livers, and lungs of WT and Arrb2−/− 6-week-old male mice (n = 6 per group) intraperitoneally injected with PBS or HSV-1 (2 × 10^7 PFU per mouse) for 48 h (***P < 0.0001 in all panels). b The virus titers as in a (***P < 0.0001 in all panels). c VSV (5 × 10^7 PFU per mouse) infection as in a (***P < 0.0001 in all panels). d The virus titers as in c (***P < 0.0001 in all panels). e, f Microscopy of hematoxylin- and eosin-stained lung and spleen sections as in a or c. g, h Survival of WT and Arrb2−/− 6-week-old male mice (n = 6 per group) infected intraperitoneally with a high dose of HSV-1 (2 × 10^8 PFU per mouse) g (*P = 0.0430) or VSV (5 × 10^8 PFU per mouse) h (*P = 0.0411) and monitored for 15 days. Data are representative of at least three independent experiments (mean ± SEM, two-tailed unpaired Student’s t-test in a–d or Kaplan–Meier analysis in g, h).
enhanced the interaction between Flag-tagged cGAS and HA-tagged cGAS (Fig. 4m). Moreover, we detected the production of cGAMP measured by the dimerization of IRF314. In fact, extracts from HT-DNA-stimulated Arrb2−/− peritoneal macrophages exhibited less cGAMP activity compared with that from WT macrophages, which resulted in reduced IRF3 dimerization in the permeabilized peritoneal macrophages (Fig. 4n), suggesting that β-arrestin 2 deficiency impaired the production of cGAMP. We next examined the dimerization of STING and found that knockdown or knockout of β-arrestin 2 decreased, but β-arrestin 2 overexpression increased the dimerization of STING (Fig. 4o, p, q). Taken together, these findings suggested that β-arrestin 2...
directly interacted with cGAS and promoted IFN-β signaling by enhancing the DNA-binding ability of cGAS.

As β-arrestin 2 also influenced the VSV-induced activation of IFN-β signaling, while only binding with cGAS directly, we thought that there might exist some other proteins that could be associated with β-arrestin 2. β-arrestin 2 did not associate with TBK1 or TRAF3 without virus infection, while the situation changed after infection. We found that endogenous β-arrestin 2 could be associated with TBK1 and TRAF3 during virus infection (Supplementary Fig. 2h). Furthermore, β-arrestin 2 could promote the interaction between TBK1 and TRAF3, which might explain why β-arrestin 2 could promote poly(I:C)- and VSV-induced activation of IFN-β signaling (Supplementary Fig. 2i).

Deacetylation of β-arrestin 2 at Lys171 enhanced the antiviral immune response. As β-arrestin 2 expression was decreased after the virus infection, which might be a smart immune evasion strategy by viruses, we conducted mass spectrometry analysis of β-arrestin 2 in the presence or absence of HSV-1 infection. This analysis revealed that the acetylation at Lys171 and Lys227 sites and the ubiquitination at Lys12, Lys18, Lys171, Lys178, and Lys227 sites were changed after HSV-1 infection. Interestingly, the Lys171 site of β-arrestin 2 was acetylated before infection but was ubiquitinated after HSV-1 infection (Supplementary Fig. 3a), suggesting that acetylation and ubiquitination regulated the degradation of β-arrestin 2. We replaced the lysines with arginines (acetylation-mimetic mutants), overexpressed WT β-arrestin 2 and these mutants in HeLa cells, and then infected them with HSV-1 or VSV to detect the expression of Ifnb. We observed that K171R mutant promoted but K171Q inhibited the expression of Ifnb, which indicated that Lys171 is a pivotal residue for β-arrestin 2 function (Fig. 5a). Similar results were obtained with the luciferase assay (Fig. 5b). Furthermore, the production of Ifnb, Isg15, and Ccl5 was increased in Arrb2−/− mouse embryonic fibroblasts (MEFs) transfected with K171R mutant compared with WT β-arrestin 2, whereas K171Q mutant abolished the positive regulation during virus infection (Fig. 5c and Supplementary Fig. 3b, c). Consistent with this observation, K171R mutant inhibited but K171Q mutant promoted the virus titers (Fig. 5d). Furthermore, K171R mutant enhanced the phosphorylation of TBK1, IRF3, IRF7, and STING and the dimerization and translocation of IRF3, compared with WT β-arrestin 2, whereas K171Q mutant abolished these functions (Fig. 5e–g, and Supplementary Fig. 3d, e, f). These findings suggested that the deacetylation of β-arrestin 2 at Lys171 was necessary for positive regulation of the IFN-β signaling.

To explore the contribution of Lys171 in β-arrestin 2 to the regulation of cGAS, we detected the interaction between β-arrestin 2 mutants and cGAS and found that the interaction was enhanced by K171R mutant (Fig. 5h). Meanwhile, we observed that the DNA-binding ability of cGAS was further enhanced by K171R mutant but abrogated by K171Q mutant (Fig. 5i), as well as the dimerization of cGAS (Fig. 5j), the production of cGAMP (Fig. 5k), and the subsequent dimerization of STING (Fig. 5l), indicating that the deacetylation of β-arrestin 2 at Lys171 residue was necessary for promoting cGAS activation. Meanwhile, K171R mutant further enhanced the interaction between TBK1 and TRAF3 compared to WT β-arrestin 2 (Supplementary Fig. 3g).

Next, we analyzed the acetylation of β-arrestin 2 during virus infection and found that β-arrestin 2 was rapidly deacetylated after infection (Fig. 5m and Supplementary Fig. 3h). We also found that ubiquitination of β-arrestin 2 was significantly increased 12 h after infection, which was coincident with the degradation of β-arrestin 2 (Figs. 1a and 5m and Supplementary Fig. 3h). Consistently, we found that the degradation of β-arrestin 2 could be rescued by MG-132 after virus infection in peritoneal macrophages (Supplementary Fig. 3i, j). Furthermore, the acetylation of K171R mutant was significantly decreased and not further reduced after the infection, whereas the acetylation of K171Q mutant remained invariant at a high level after the infection (Fig. 5n). Consistent with the results that the ubiquitination of both K171R and K171Q mutants was abolished, these two mutants were not degraded after the infection (Fig. 5o and Supplementary Fig. 3k), which indicated that the ubiquitination at Lys171 residue induced the degradation of β-arrestin 2. As the deacetylation (1 h after infection) of β-arrestin 2 occurred before the ubiquitination and degradation (12 h after infection) during infection, we supposed that Lys171 was deacetylated before being ubiquitinicated to positively regulate the IFN-β signaling.

Carvedilol promoted the antiviral immune response through β-arrestin 2. It has been reported that carvedilol could increase β-arrestin 2 expression in a rat acute myocardial infarction model and regulate β1,4AR signaling42-44; therefore, we speculated whether carvedilol could play a role in virus infection through β-arrestin 2. We first confirmed the function of carvedilol against virus infection in vivo. The results demonstrated that carvedilol promoted the production of Ifnb, Isg15, and Ccl5 and reduced the virus titers in the spleens, livers, and lungs of WT mice after virus infection (Fig. 6a-d). Consistent with this finding, the injury in the lungs (Fig. 6e) and spleens (Fig. 6f) was less, and the survival rates were higher (Fig. 6g, h) after treatment with carvedilol. In agreement with the in vivo results, the production levels of Ifnb, Isg15, and Ccl5 were much higher in the carvedilol-treated WT peritoneal macrophages (Fig. 7a, b), whereas the virus titers were lower (Fig. 7c, d) after the infection. Furthermore, carvedilol increased the phosphorylation of TBK1, IRF3, IRF7, and STING (Fig. 7e, f) and the dimerization and translocation of IRF3 (Fig. 7g–j) after the infection. We also detected the production of Ifnb, Isg15, and Ccl5 in spleens, livers and lungs in Arrb2−/− mice. We found that carvedilol had no effect on the production of above cytokines in Arrb2−/− mice after HSV-1 infection.
production of Ifnb, Isg15, Ccl5 (Supplementary Fig. 4a). Besides, carvedilol did not increase the mRNA (fold × 10^2) of the genes IRF3, IRF7 and STING in Arrb2^-/- peritoneal macrophages (Supplementary Fig. 4b). These results indicated that carvedilol promote type I IFN signaling through β-arr2.

As β-arr2 expression was higher in the carvedilol-treated group than in the control group 12 h after the infection (Fig. 7e), we hypothesized that β-arr2 degraded by virus infection was rescued by carvedilol to positively regulate the IFN-β signaling and the antiviral innate immune response. Furthermore,
Fig. 5 Deacetylation of β-arrestin 2 at Lys171 enhanced the antiviral immune response. a) Ifnb mRNA level in HeLa cells transfected with control vector, β-arrestin 2, or β-arrestin 2 mutants and infected with HSV-1 (left) or VSV (right) for 16 h (*P < 0.0001, **P = 0.0067, ***P < 0.0001, left panel; ***P = 0.0003, **P = 0.0133, ***P = 0.0003, right panel). b) Luciferase assay of IFN-β activation in HEK293T cells expressing various vectors (**P < 0.0001, ***P = 0.0017, **P < 0.0001). c) Ifnb mRNA level in Arrb2−/− MEFs transfected with control vector, β-arrestin 2, or β-arrestin 2 mutants and infected with HSV-1 (left) or VSV (right) for 16 h (*P < 0.0001, **P = 0.0032, ***P = 0.0003, left panel; **P < 0.0001, < 0.0001, = 0.0005 in sequence, right panel). d) The virus titers as in c for 72 h (**P = 0.0006, = 0.0003, < 0.0007 in sequence, left panel; **P < 0.0001, **P = 0.00014, 0.0012 in sequence, right panel). e) Immunoassay of lysates of Arrb2−/− MEFs transfected as in c and infected with HSV-1 for indicated times. f) Immunoassay analysis of monomeric and dimeric IRF3 as in e. g) Immunoassay analysis of lysates of HEK293T cells expressing various vectors. h) Immunoassay analysis of cell lysates and streptavidin-precipitated proteins from HEK293T cells transfected with various vectors and stimulated with biontin-β-3D. i) Immunoassay of lysates of HEK293T cells expressing various vectors. k) cGAMP activity measured by extracts from HT-DNA-stimulated (6 h) Arrb2−/− MEFs transfected with various vectors. l) Immunoassay analysis of monomeric and dimeric IFR3 as in f. m) Immunoassay of lysates of peritoneal macrophages infected with HSV-1 for indicated times. n) Immunoassay of lysates of Arrb2−/− MEFs transfected as in l and infected with HSV-1 for 4 h. o) Immunoassay of lysates as in n for 24 h. Data are representative of at least three independent experiments (mean ± SEM in b-d, n = 3). Two-tailed unpaired Student's t-test.

...ce we evaluated the molecular mechanism of carvedilol on the β-arrestin 2-cGAS–STING–IFR3 axis and found that carvedilol significantly enhanced the interaction between β-arrestin 2 and cGAS (Fig. 7k), the DNA-binding ability of cGAS (Fig. 7l), the production of cGAMP (Fig. 7m), and the dimerization of STING (Fig. 7n). In consideration of the pivotal role of Lys171, we also detected the deacetylation of β-arrestin 2 after carvedilol treatment and observed that carvedilol promoted the deacetylation of β-arrestin 2 during infection (Fig. 7o, p).

To elucidate the relationship between carvedilol and Lys171 of β-arrestin 2, we infected Arrb2−/− MEFs with HSV-1 and VSV, which were overexpressed with WT β-arrestin 2 and its mutants, and treated with carvedilol before lysed. The results showed that carvedilol only enhanced the activity of WT β-arrestin 2 but not β-arrestin 2 mutants in the production of Ifnb, Isg15, Ccl5, virus titers, the phosphorylation of TBK1, IRF3, IRF7, STING, the dimerization, and translocation of IFR3 (Supplementary Fig. 5a-g). Furthermore, we detected the interaction between β-arrestin 2 mutants and cGAS, the binding activity between cGAS and dsDNA, the production of cGAMP, and the dimerization of STING, and found that the function of WT β-arrestin 2, but not β-arrestin 2 mutants, was further promoted by carvedilol (Supplementary Fig. 5h-k). Meanwhile, the interaction between TBK1 and TRAF3 was promoted not only by carvedilol alone, but also through β-arrestin 2 (Supplementary Fig. 5i). And also, the interaction between TBK1 and TRAF3 was further promoted by K171R mutant compared to WT β-arrestin 2, while there was no difference with carvedilol treatment (Supplementary Fig. 5m). Together, we thought that carvedilol activated β-arrestin 2 through Lys171. These data revealed that carvedilol positively regulated IFN-β signaling and antiviral immunity by preventing the degradation of β-arrestin 2 and promoting the deacetylation of β-arrestin 2 at Lys171, thus indicating that β-arrestin 2 could be a novel drug candidate for the treatment of virus infection.

Discussion

Studies have reported that β-arrestin 2 is widely involved in a variety of signaling pathways and functions in multiple diseases, including nervous and metabolic disorders and several cancers. Furthermore, β-arrestin 2 inhibits the activation of the TRAF6-NF-κB pathway by preventing the self-oligomerization of TRAF6 or inhibiting the release of p65 from IκB. However, whether and how β-arrestin 2 regulates the host antiviral innate immune response remain unknown. In the present study, we found that Arrb2−/− mice exhibited lower IFN-β production, higher virus titers in tissues, and decreased survival rates than their WT littermates. Moreover, β-arrestin 2 promoted the activation of the IFN-β signaling pathway by targeting cGAS, which was completely different from the function of β-arrestin 2 in the NF-κB signaling pathway. From the perspective of viruses, they were so smart that they could inhibit the expression of β-arrestin 2 by regulating its acetylation and ubiquitination to evade the host immune response. In addition, except that viruses inhibited positive regulators, such as β-arrestin 2, to achieve immune evasion in the present study, some other viruses also use the opposite strategy that enhances the expression of negative regulators to eventually evade the host immune response. For example, one of our previous studies demonstrated that virus-induced PLCβ2 negatively regulates virus-induced proinflammatory responses by inhibiting the activation of TAK1. However, while the devil climbs a post, the priest climbs ten. The clinically proven drug carvedilol rescued the degradation of β-arrestin 2 and promoted the activation of IFN-β signaling and the antiviral immune response, indicating that it might be an efficient antiviral drug candidate to treat virus infection.

We detected the activation of three major signaling pathways in virus infection, including the cGAS–STING, the NF-κB, and MAPK pathways, and found that β-arrestin 2 promoted only the activation of the cGAS–STING pathway but had no effect on the other two pathways. In addition, we observed that β-arrestin 2 enhanced the activation of the cGAS–STING pathway by promoting the recognition of dsDNA by cGAS and the subsequent production of cGAMP. However, the detailed mechanism through which β-arrestin 2 regulates the activation of cGAS and the pivotal residues in cGAS that mediates the activation still need to be further elucidated. Moreover, no study has yet confirmed the enzymatic activity of β-arrestin 2, and it is necessary to further elucidate whether β-arrestin 2 directly regulates or recruits other enzymes to regulate cGAS activation.

We observed that β-arrestin 2 was ubiquitinated and degraded 12 h after infection, whereas it was deacetylated only 1 h after infection, indicating that β-arrestin 2 could normally promote the activation of IFN-β signaling and the antiviral immune response at the early stage of infection, which was decreased by virus-induced ubiquitination and degradation of β-arrestin 2 in the late stage. However, this type of degradation was not a thorough process. In this case, β-arrestin 2 was still expressed at a relatively lower level so that it could promote the antiviral immune response to some extent. We suppose that this smart and accurate strategy of immune evasion was developed during the co-evolution of host and viruses to achieve their symbiosis. This mechanism also preserved the antiviral immune response at a relatively lower level but avoided the production of a strong cytokine storm, which was another smart strategy for the viruses to achieve the symbiosis with the host. Based on the results of mass spectrometry analysis, we assumed that Lys171 is an important residue as it could be acetylated and ubiquitinated,
which mediated the acetylation and degradation of β-arrestin 2. We found that β-arrestin 2 was rapidly deacetylated after virus infection. The acetylation-defective mutant of β-arrestin 2 (K171R) enhanced but the acetylation-mimetic mutant (K171Q) impaired the activation of IFN-β signaling compared with the WT β-arrestin 2. We also found that K171R and K171Q were not degraded after virus infection. Thus, the acetylation and ubiquitination of β-arrestin 2 at Lys171 might mediate the function of
β-arrestin 2 in the activation of the IFN-β signaling pathway, the specific mechanism of which needs to be further investigated.

In addition, we demonstrated that the β-blocker carvedilol rescued the expression of the virus infection-degraded β-arrestin 2, which further enhanced the antiviral immune response. Carvedilol also promoted the deacetylation of β-arrestin 2 after virus infection, which might partially explain why carvedilol could increase the expression of β-arrestin 2 and improve the antiviral immune response. These findings revealed that carvedilol might promote the antiviral innate immune response by enhancing β-arrestin 2 expression, which may be an outstanding example of the novel use of a conventional drug to treat viral infectious diseases.

Altogether, our study findings have identified β-arrestin 2 as a positive regulator of precise control of the cellular antiviral immune response through regulating cGAS activation and IFN-β production. This result should open up new perspectives on the regulation of the cGAS–STING signaling pathway. Furthermore, our study has shed light on the novel mechanism of immune evasion by viruses and the possibility for the novel use of the conventional drug carvedilol as a potential drug candidate for the treatment of viral infectious diseases.

Methods

Reagents and plasmids. The following chemical reagents and antibodies were used in this study: anti-TBK1 (3504), anti-phospho-TBK1 (5483), anti-phospho-IRF3 (29047), anti-phospho-IRF7 (24129), anti-phospho-beta-arrestin-2 (9215), anti-phospho-Erk1/2 (9101), anti-STING (13647), anti-cGAS (15102), anti-RIG-1 (4200), anti-phospho-STING (72971), and anti-β-arrestin 2 (3857 S; all from Cell Signaling Technology); anti-Flag M2 Affabcam) are diluted in the ratio of 1:1000; anti-Flag-RIG-I, anti-Flag-RIG-I-N, both from Cwbio) are diluted in the ratio of 1:10,000; and Protein G Sepharose 4 Fast Flow (GE Healthcare). Expression constructs for Flag-RIG-I, Flag-RIG-I-N, Flag-TBK1, Flag-IRF3, Flag-cGAS, Flag-TRAF3, HA-cGAS, HA-CK1e, and HA-Ubs were obtained from Dr. B. Ge (Tongji University, Shanghai, China), and Flag-STING was obtained from Dr. B. Sun (Shanghai Institute of Biochemistry and Cell Biology, Shanghai, China). Site-directed point mutagenesis of β-arrestin 2 was performed using the KOD Plus Mutagenesis Kit (SMK101, TOYOBO) according to the manufacturer’s instructions.

Cells and viruses. Mouse peritoneal macrophages, MEFs, and RAW264.7, 12.9, and HEK293T cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; HyClone) supplemented with 10% (v/v) heat-inactivated FBS (Gibco) and 100 U/ml penicillin and streptomycin (HyClone). HeLa cells were cultured in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated FBS (Gibco) and 100 U/ml penicillin and streptomycin (HyClone). Vero cells were cultured in DMEM supplemented with 3% (v/v) heat-inactivated FBS (Gibco). HSV-1, VSV, and SeV were obtained from Dr. B. Ge (Tongji University, Shanghai, China). Mouse strains. Homozygous Arrb2−/− mice (from Dr. G. Pei, Tongji University, Shanghai, China) were bred under specific pathogen-free conditions at the Shanghai Research Center for Biomodel Organisms. Six-week-old male specific pathogen-free (SPF) Arrb2−/− mice and their WT littermates used in the experiments were bred separately and put to death by cervical vertebra dislocation.

RNA-seq library preparation, sequencing, and data processing. WT and Arrb2−/− PMs treated for 16 h with HSV-1 before they were lysed with RNAlater Plus according to the manufacturer’s instructions. The lysates were sent to Personalbio for cDNA library construction and sequencing by Illumina NovaSeq 6000. RNA-sequencing reads were first trimmed to remove poly(A) and unqualified reads with cutadapt, then aligned to Mus musculus GRCh38 genome with Ensembl. The number of counts was summarized at the gene level using HTseq. Gene expression values were computed from fragments per kilobase of million fragments (FPKM) values produced by addition of a pseudocount of 1 and log2 transformation of the results. These FPKM values were used for drawing the heatmap with the heatmap R package. Pairwise differential gene expression analyses were performed with DESeq R package by addition of fold change > 2 and p-value < 0.05. Volcano plots of these differential genes were drawing with ggplot2 R package. GO or KEGG enrichment analyses of differential genes were performed using topGO or KAAAS, respectively. The terms or pathways involved in host antiviral immune response with fold change > 2 and p-value < 0.05 were used for drawing GO term enrichment or KEGG pathway enrichment. The PPI analysis of differential genes was performed with STRING database and PPI network model was drawn with CytoScape.

Quantitative real-time PCR. Cells were incubated for 12 h with DMEM and then infected with the viruses for the indicated times. Total RNA was isolated using RNAlater Plus (Takara) according to the manufacturer’s instructions. Then, 1 μg of RNA was reverse-transcribed using the FirstScript μL Reverse Transcription Kit (RO37; Takara) to generate cDNA. A LightCycler (LC40; Roche) and a SYBR RT-PCR Kit (QPK-212; ToyoBO) were used for quantitative real-time RT-PCR analysis. Gene amplification was performed using the ΔΔCt method. Gene expression was normalized to that of GAPDH. The primer sequences used to amplify human and mouse genes are described in Supplementary Table 1.

Immunoprecipitation and Western blotting. Cells were transfected with the indicated plasmids. After 48 h, cells were lysed in a lysis buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, and 1 mM EDTA (pH 8.0)) supplemented with a protease cocktail (Roche, 0469315901) consisting of 1 mM PMSF, 1 mM Na3VO4, and 1 mM NaF for 30 min on ice. The lysates were centrifuged at 15,000 rpm for 15 min at 4 °C to remove the debris. Cell lysates were incubated with anti-Flag M2 Affinity Gel or Protein G Sepharose 4 Fast Flow plus pre-bound antibodies at 4 °C overnight. For immunoprecipitation of endogenous protein, mouse peritoneal macrophages or HeLa cells were lysed and incubated
with the specified antibodies and Protein G Sepharose 4 Fast Flow at 4 °C overnight. The sepharose samples were centrifuged and washed three times with ice-cold PBST buffer (1% Triton X-100 in PBS). Precipitates or cell lysates were boiled in 1× SDS loading buffer at 100 °C for 10 min and then analyzed by immunoblotting.

GST pull-down. His or GST fusion proteins were expressed in BL-21(DE3) (Tiangen Biotech) according to the manufacturer’s instructions. GST fusion proteins were lysed by ultrasonication, incubated with GST beads for 4 h at 4 °C, and then washed three times with TBST to collect the precipitates. Purified His fusion protein or lysates of mouse peritoneal macrophages were incubated with the
collected precipitates for 4 h at 4 °C. After centrifugation and washing, the beads were boiled in 1× SDS loading buffer at 100 °C for 10 min and then analyzed by immunoblotting.

Native PAGE. The dimerization assay was performed as described. In brief, mouse peritoneal macrophages or L929 cells were cultured in DMEM for 12 h and infected with virus for the indicated times. Cells were harvested using 100 μl ice-cold lysis buffer (50 mM Tris, pH 7.4; 150 mM NaCl; 1% Triton X-100; 1 mM EDTA, pH 8.0; and 1 mM DTT, and 1 mM PMSF) at 4 °C. The homogenates were quantified and diluted with 2× native PAGE sample buffer (125 mM Tris-HCl, pH 6.8; 30% glycerol; and 0.1% bromophenol blue). Then, 30 μg of protein was applied to a pre-run 7.5% native gel. After electrophoresis, the proteins were transferred onto a nitrocellulose membrane for immunoblotting.

In vitro assay for cGAMP activity. WT or Arrb2−/− mouse peritoneal macrophages were left untreated or treated with HT-DNA for 6 h and homogenized by bouncing in the lysis buffer (10 mM Tris-HCl, pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM DTT, and 1 mM PMSF) at 4 °C. The homogenates were centrifuged at 10,000 rpm for 20 min at 4 °C. After heating at 95 °C for 5 min, the supernatant was centrifuged again at 12,000 rpm for 10 min to remove precipitates. The lysates were mixed with fresh WT mouse peritoneal macrophages in 12.5 μl reaction buffer containing 2 mM ATP, 1 U/ml Benzonase, and 2 μg/ml PFO for 2 or 4 h at 37 °C. The cells were then subjected to the Native PAGE assay.

Cell staining and confocal microscopy. HeLa cells were transfected with the appropriate plasmids for 48 h and infected with HIV-1 or HSV for the indicated times. Peritoneal macrophages were infected with viruses directly. Cells were fixed with 4% formaldehyde for 20 min at room temperature, permeabilized for 30 min in PBS containing 0.3% Triton X-100, and then blocked for 1 h at 4 °C in a blocking buffer (1% BSA in PBS). Then, the cells were incubated with the indicated antibodies overnight and secondary antibodies at room temperature for 1 h. After staining with DAPI, images were obtained using a Leica TCS SP5 confocal laser microscopy system.

Dual-luciferase reporter assay. HEK293T cells were transiently transfected with pRL-IFN-β–Luc or pRL-ISE-Luc, pRL-TK, and the indicated plasmids for 24 h. Dual-luciferase reporter assay system (Roche; Beyotime) was used to detect the luciferase activity according to the manufacturer’s instructions.

Electrophoretic mobility shift assay (EMSA). To conduct the EMSA, we firstly prepared the lysates of competent E. coli transformed with β-arrestin 2 and cGAS plasmids for the DNA–protein conjugation reaction and measured the protein concentration by BCA protein assay kit (Beyotime, P0012). We synthesized biotin-labeled ISD probe for EMSA assay (Sangon Biotech). Then we executed the DNA–protein binding reactions using EMSA Gel-Shift Kit (Beyotime,GS009) following the manufacturer’s instructions at 25 °C. Finally, the reaction mixture was separated through 4% non-denaturing PAGE gels and developed.

Statistical analysis. Data are expressed as mean ± standard error of the mean (SEM). Prism 6 (GraphPad) is used for statistical analyses. The statistical tests conducted in this study are indicated in the figure legends as follows: *P < 0.05; **P < 0.01; ***P < 0.001, two-tailed unpaired Student’s t-test. Leica TCS SP8 confocal laser microscopy system is used for Immunohistochemistry data. Viia 7 software v1.2.4 on Viia 7DX is used for qRT-PCR data analysis. ImageQuant LAS 4000mini and Amersham Image 600 is used for western blot data. RNA-seq data are analyzed by cutadapt, Ensemble, HTseq, phatmap R package, DEseq2 R, ggplot2 R, topGO, KEGG, STRING database, and Cytoscape as described in RNA-seq library preparation, sequencing and data processing section. Illumina NovaSeq 6000 is used for RNA sequencing.

Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability. The authors declare that the data supporting the findings of this study are available within the paper and its supplementary information files. Source data are provided with this paper. All other data associated with the results of the study will be available from the corresponding author upon reasonable request. The RNA-seq data have been deposited in Gene Expression Omnibus (GEO) under the GSE19755. Source data are provided with this paper.

Received: 2 April 2020; Accepted: 3 November 2020; Published online: 26 November 2020

References

1. The, L. Emerging understandings of 2019-nCoV. Lancet 395, 311 (2020).
2. Holshue, M. L. et al. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med. 382, 929–936 (2020).
3. Rothe, C. et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N. Engl. J. Med. 382, 970–971 (2020).
4. Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Recognition of double-stranded RNA and activation of NF-κB by toll-like receptor 3. Nature 413, 732–738 (2001).
5. Wu, J. & Chen, Z. J. Innate immune sensing and signaling of cytosolic nucleic acids. Annu. Rev. Immunol. 32, 461–488 (2014).
6. Liyu, T. et al. Induction of OTU4D by viral infection promotes antiviral responses through des ubiquitinizing and stabilizing MAVS. Cell Res. 29, 67–79 (2019).
7. Zhang, S. et al. Small-molecule inhibition of TLR8 through stabilization of its resting state. Nat. Chem. Biol. 14, 58–64 (2018).
8. Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303, 1526–1529 (2004).
9. Takeuchi, O. & Akira, S. Pattern recognition receptors and innate immunity. Cell 140, 805–810 (2010).
10. Jiang, Z., Mak, T. W., Sen, G. & Li, X. Toll-like receptor 7 and 8. Nature Rev. Immunol. 10, 643–655 (2010).
11. Kato, H. et al. Differential roles of MDA5 and RIG-I in sensing viral RNA and regulating innate immune adjuvant effects. N. Engl. J. Med. 371, 1390–1399 (2014).
12. Ablasser, A. & Hur, S. Regulation of cGAS- and RLR-mediated immunity to nucleic acids. Nat. Immunol. 20, 249–259 (2019).
13. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 796–801 (2013).
14. Jiang, Z., Mak, T. W., Sen, G. & Li, X. Toll-like receptor 3-mediated activation of NF-κBappa and IRF3 diverges at Toll-I-1 receptor domain-containing adapter inducing IFN-beta. Proc. Natl Acad. Sci. USA 101, 1353–1358 (2004).
15. Kato, H. et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101–105 (2006).
16. Ablasser, A. & Hur, S. Regulation of cGAS- and RLR-mediated immunity to nucleic acids. Nat. Immunol. 20, 249–259 (2019).
17. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 796–801 (2013).
18. Wu, J. et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339, 826–830 (2013).
19. Ye, W. et al. TRIM8 negatively regulates TLR3-mediated innate immune response by blocking TRIF-TBK1 interaction. J. Immunol. 199, 1856–1864 (2017).
20. Seth, R. B., Sun, L., Ea, C. K. & Chen, Z. J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κBappa and IRF 3. Cell 122, 669–682 (2005).
21. Li, X. D. et al. Pivotal roles of cGAMP-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 341, 1390–1394 (2013).
22. Zhang, C. et al. Structural basis of STING binding with and phosphorylation by TBK1. Nature 567, 394–398 (2019).
23. Ishikawa, H. & Barber, G. N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674–678 (2008).
20. Civril, F. et al. Structural mechanism of cytosolic DNA sensing by cGAS. *Nature* **498**, 332–337 (2013).
21. Du, M. & Chen, Z. J. DNA-induced liquid phase condensation of cGAS activates innate immune signaling. *Science* **361**, 704–709 (2019).
22. Xie, W. et al. Human cGAS catalytic domain has an additional DNA-binding interface that enhances enzymatic activity and liquid-phase condensation. *Proc. Natl Acad. Sci. USA* **116**, 11946–11955 (2019).
23. Hu, M. M. et al. Sumoylation promotes the stability of the DNA sensor cGAS and the adaptor STING to regulate the kinetics of response to DNA virus. *Immunity* **45**, 555–569 (2016).
24. Dai, J. et al. Acetylation blocks cGAS activity and inhibits self-DNA-induced autoimmunity. *Cell* **176**, 1447–1460 (2019).
25. Wang, Q. et al. The E3 ubiquitin ligase RNF185 facilitates the cGAS-mediated innate immune response. *Proc. Natl Acad. Sci. USA* **113**, 1006264 (2017).
26. Barnett, K. C. et al. Phosphoinositide interactions position cGAS at the plasma membrane to ensure efficient distinction between self- and viral DNA. *Cell* **176**, 1432–1446 (2019).
27. Gentili, M. et al. The N-terminal domain of cGAS determines preferential association with centromeric DNA and innate immune activation in the nucleus. *Cell Rep.* **26**, 3798 (2019).
28. Liu, H. et al. Nuclear cGAS suppresses DNA repair and promotes tumorigenesis. *Nature* **563**, 131–136 (2018).
29. Chen, W. et al. Activity-dependent internalization of smoothened mediated by beta-arrestin 2 and GRK2. *Science* **306**, 2257–2260 (2004).
30. Chen, W. et al. Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. *Science* **301**, 1394–1397 (2003).
31. Chen, W. et al. Dishevelled 2 recruits beta-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. *Science* **301**, 1391–1394 (2003).
32. Luttrel, L. M. & Lefkowitz, R. J. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. *J. Cell Sci.* **115**, 4585–4593 (2002).
33. Ma, L. & Pei, G. Beta-arrestin signaling and regulation of transcription. *J. Cell Sci.* **120**, 213–218 (2007).
34. Zhu, J. et al. Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of beta-arrestin2 and NLRP3. *Cell Death Differ.* **25**, 2037–2049 (2018).
35. Infante, P. et al. Ich5/beta-arrestin2-dependent non-proteolytic ubiquitination of SuFu controls Hedgehog signalling and medulloblastoma tumorigenesis. *Nat. Commun.* **9**, 976 (2018).
36. Wang, H. et al. Beta-arrestin2 functions as a key regulator in the sympathetic-arrestin-mediated EGFR transactivation. *Proc. Natl Acad. Sci. USA* **106**, 6650–6655 (2009).
37. Walker, J. K. et al. Beta-arrestin-2 regulates the development of allergic asthma. *J. Clin. Investig.* **112**, 566–574 (2003).
38. Shenoy, S. K. et al. Beta-arrestin-dependent signaling and trafficking of 7-transmembrane receptors is reciprocally regulated by the deubiquitinating USP33 and the E3 ligase Mdm2. *Proc. Natl Acad. Sci. USA* **106**, 6650–6655 (2009).
39. Lee, S. H., Hollingsworth, R., Kwon, H. Y., Lee, N. & Chung, C. Y. Beta-arrestin 2-dependent activation of ERK1/2 is required for ADP-induced paxillin phosphorylation at Ser(83) and microglia chemotaxis. *Glia* **60**, 1366–1377 (2012).
40. Gao, H. et al. Identification of beta-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways. *Mol. Cell* **14**, 303–317 (2004).
41. Wang, Y. et al. Association of beta-arrestin and TRAF6 negatively regulates toll-like receptor-interleukin 1 receptor signaling. *Nat. Immunol.* **7**, 139–147 (2006).
42. Kim, I. M. et al. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. *Proc. Natl Acad. Sci. USA* **105**, 14555–14560 (2008).
43. Wisler, J. W. et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. *Proc. Natl Acad. Sci. USA* **104**, 16657–16662 (2007).
44. Liu, C. C., Huang, Y., Zhang, J. H., Xu, Y. & Wu, C. H. Effect of carvedilol on cardiac dysfunction 4 days after myocardial infarction in rats: role of toll-like receptor 4 and beta-arrestin 2. *Eur. Rev. Med. Pharmacol. Sci.* **17**, 2103–2110 (2013).
45. Andreeva, L. et al. cGAS senses long and HMGB/TFAM-bound U-turn DNA by forming protein-DNA ladders. *Nature* **549**, 394–398 (2017).
46. Pydi, S. P. et al. Adipocytok beta-arrestin-2 is essential for maintaining whole body glucose and energy homeostasis. *Nat. Commun.* **10**, 2936 (2019).
47. Infante, P. et al. Ich5/beta-arrestin2-dependent non-proteolytic ubiquitination of SuFu controls Hedgehog signalling and medulloblastoma tumorigenesis. *Nat. Commun.* **9**, 976 (2018).
48. Wang, L. et al. PLCbeta2 negatively regulates the inflammatory response to virus infection by inhibiting phosphoinositide-mediated activation of TAK1. *Nat. Commun.* **10**, 746 (2019).

Acknowledgments
We thank Dr. G. Pei (Tongji University, Shanghai, China) for providing *Arbuz*−/− mice, Dr. B. Ge (Tongji University, Shanghai, China) for providing SeV, VSV, HSV-1, and expression constructs for Flag-RIG-1, Flag-N-RIG-1, Flag-TBK1, Flag-IRF3, Flag-cGAS, Flag-TRAF3, HA-cGAS, HA-CK1*, and HA-ubiquitinations and Dr. B. Sun for providing Flag-STING from (Shanghai Institute of Biochemistry and Cell Biology, Shanghai, China). This work was supported by grants from the National Natural Science Foundation of China (project 31972900 and 31670901), the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (program TP2016007), the Outstanding Youth Training Program of Shanghai Municipal Commission of Health and Family Planning (program 2017Y0012), Innovative Research Team of High-level Local Universities in Shanghai, the National Key Research and Development Program of China (program 2016YFC1305103 and 2018YFC1705505), and the National megaproject on key infectious diseases (program 2017ZX10202102).

Author contributions
Y.Z. and D.Y. designed this study; Y.Z. and M.L. performed the experiments assisted by L.L., G.Q., Y.W., Z.C., J.L., C.F., and F.H.; D.G., Z.Q., and Y.C. contributed to discussions and agreement with the conclusions; Y.Z. and D.Y. analyzed the data and wrote the manuscript; and all authors discussed the results and commented on the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-020-19849-9.

Correspondence and requests for materials should be addressed to D.Y.

Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this paper. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020